Alexion Pharma (ALXN) Tops Q4 EPS by 32c, FY EPS Guidance Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Reports Fourth Quarter and Full Year 2018 Results
February 4, 2019 6:30 AM EST4Q18 total revenues of $1,128.8 million, a 24 percent increase over 4Q17 and a 30 percent volume increase 4Q18 GAAP diluted EPS of $(0.20); non-GAAP diluted EPS of $2.14 2019 guidance: revenue $4,625 to $4,700 million; GAAP diluted EPS of $6.14 to $7.26; non-GAAP diluted EPS of $9.10 to $9.30 SOLIRIS® (eculizumab) for Generalized Myasthenia Gravis (gMG) best Alexion launch in first year following regulatory approval U.S. launch underway for ULTOMIRIS (ravulizumab-cwvz) in adults with paroxysmal nocturnal hemoglobinuria (PNH); EU and Japanese applications under review... More
